Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Simon T. Durrant; Arnon Nagler; Paola Guglielmelli; David Lavie; Philipp le Coutre; Heinz Gisslinger; Charles Chuah; Margherita Maffioli; Savita Bharathy; Tuochuan Dong; Monika Wroclawska; Joaquin Martinez Lopez

doi:10.3324/haematol.2018.209965

Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Simon T. Durrant^*, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, Joaquin Martinez Lopez

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

30 Scopus citations

Original language	English
Pages (from-to)	E551-E554
Journal	Haematologica
Volume	104
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2018.209965
State	Published - 2019
Externally published	Yes

Funding

Funders	Funder number
Novartis Pharmaceuticals Corporation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3324/haematol.2018.209965

Cite this

Durrant, S. T., Nagler, A., Guglielmelli, P., Lavie, D., le Coutre, P., Gisslinger, H., Chuah, C., Maffioli, M., Bharathy, S., Dong, T., Wroclawska, M., & Lopez, J. M. (2019). Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica, 104(12), E551-E554. https://doi.org/10.3324/haematol.2018.209965

@article{a95f84479e9e450a9d4d2b0ddb5e23f2,

title = "Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis",

author = "Durrant, {Simon T.} and Arnon Nagler and Paola Guglielmelli and David Lavie and {le Coutre}, Philipp and Heinz Gisslinger and Charles Chuah and Margherita Maffioli and Savita Bharathy and Tuochuan Dong and Monika Wroclawska and Lopez, {Joaquin Martinez}",

note = "Funding Information: the Novartis Pharmaceuticals Corporation",

year = "2019",

doi = "10.3324/haematol.2018.209965",

language = "אנגלית",

volume = "104",

pages = "E551--E554",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

Durrant, ST, Nagler, A, Guglielmelli, P, Lavie, D, le Coutre, P, Gisslinger, H, Chuah, C, Maffioli, M, Bharathy, S, Dong, T, Wroclawska, M & Lopez, JM 2019, 'Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis', Haematologica, vol. 104, no. 12, pp. E551-E554. https://doi.org/10.3324/haematol.2018.209965

Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. / Durrant, Simon T.; Nagler, Arnon; Guglielmelli, Paola et al.
In: Haematologica, Vol. 104, No. 12, 2019, p. E551-E554.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Results from Harmony

T2 - An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

AU - Durrant, Simon T.

AU - Nagler, Arnon

AU - Guglielmelli, Paola

AU - Lavie, David

AU - le Coutre, Philipp

AU - Gisslinger, Heinz

AU - Chuah, Charles

AU - Maffioli, Margherita

AU - Bharathy, Savita

AU - Dong, Tuochuan

AU - Wroclawska, Monika

AU - Lopez, Joaquin Martinez

N1 - Funding Information: the Novartis Pharmaceuticals Corporation

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85074039445&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.209965

DO - 10.3324/haematol.2018.209965

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 31073072

AN - SCOPUS:85074039445

SN - 0390-6078

VL - 104

SP - E551-E554

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Results from Harmony: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Funding

UN SDGs

Access to Document

Other files and links

Cite this